`Sent: Tuesday, September 05, 2017 10:35 AM
`To: Trials <Trials@USPTO.GOV>
`Cc: Love, Jane M. <JLove@gibsondunn.com>; Trenchard, Robert W. <RTrenchard@gibsondunn.com>;
`'ahollis@kirkland.com' <ahollis@kirkland.com>
`Subject: IPR201701946 – Petitioner’s Joinder Motion to Join IPR201700854
`
`To the Patent Trial and Appeal Board:
`
`I represent Patent Owner Novartis in the above IPRs. I write to inform the Board that Novartis does
`not object to Petitioner Teva’s and its affiliates’ Motion for Joinder of IPR201701946 with now
`instituted IPR201700854, as the Petition in IPR201701946 is substantively the same as the Petition in
`IPR201700854, and Petitioners has agreed not to pursue any arguments or make any filings separate
`from those made by the Petitioner in IPR201700854, subject to reserving Petitioners’ right to take a
`lead role in the event Apotex drops out of IPR201700854. I accordingly respectfully request that the
`Board grant Teva’s and its affiliates’ joinder motion, and Novartis hereby agrees not to submit a
`Preliminary Response to Teva’s Petition.
`
`Respectfully submitted,
`Jane M. Love, Ph.D. (Reg. No. 42,812)
`Lead Counsel for Patent Owner
`Jane M. Love, Ph.D.
`
`GIBSON DUNN
`
`Gibson, Dunn & Crutcher LLP
`200 Park Avenue, New York, NY 10166-0193
`Tel +1 212.351.3922 • Fax +1 212.351.6322
`JLove@gibsondunn.com • www.gibsondunn.com
`
`This message may contain confidential and privileged information. If it has been sent to you in error,
`please reply to advise the sender of the error and then immediately delete this message.
`
`